Richcore Lifesciences

Richcore Lifesciences Pvt. Ltd. is an innovation led biotechnology company developing novel enzymatic solutions for Industrial Biotechnology and Animal Origin Free recombinant proteins and enzymes for Biopharma. Richcore is venture and PE investment backed, and has multiple patent filings, and a high capacity GMP certified manufacturing plant. Its solutions are used in the global food, water, energy, and biopharma industries. At the root of its innovation is the vision and commitment to create cleaner, greener and sustainable solutions to tackle the current industrial problems. Richcore's corporate goals are aligned with the goals of the society at large to achieve meaningful economic development. Richcore intrinsically believes that doing well happens by doing good!

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

GLOBAL CRISPR AND CRISPR-ASSOCIATED (CAS) GENES MARKET INSIGHTS 2019-2025

Galus | April 14, 2020

news image

Manufacturing process and technology used in CRISPR And CRISPR-Associated (Cas) Genes market, key developments and trends changing in the development Complete examination, including an evaluation of the parent market...

Read More

CELL AND GENE THERAPY

BIO-TECHNE SIGNS LICENSE AGREEMENT WITH LUMINARY THERAPEUTICS FOR THE USE OF TCBUSTER™ FOR THE MANUFACTURING OF GENE-MODIFIED CELL THERAPIES

Bio-Techne | February 25, 2021

news image

Bio-Techne Corporation today declared the signing of a license agreement with Luminary Therapeutics for the utilization of TcBuster™ for the manufacturing of gene-modified cell therapies. TcBuster is Bio-Techne's proprietary non-viral transposon-based gene delivery system used to advance cell therapy manufacturing. Under the provisions of this agreement, Bio-Techne grants Luminary Therapeutics a non-exclusive license for TcBuster. Luminary Therapeutics will utilize TcBus...

Read More

CAMENA BIOSCIENCE HITS DNA SYNTHESIS MILESTONE

Labiotech | February 06, 2020

news image

Camena Bioscience has achieved a significant DNA synthesis milestone by reproducing the DNA sequence of a whole plasmid, which could be used in synthetic biology applications such as protein production and bacterial engineering. DNA synthesis is a field that, until recently, had not been a focus for companies developing innovative technologies, with greater importance being placed on DNA sequencing and manipulation tools....

Read More

INDUSTRIAL IMPACT

IFF TO ACQUIRE HEALTH WRIGHT PRODUCTS

IFF | February 17, 2022

news image

IFF announced that it has entered into an agreement to acquire Health Wright Products, LLC (HWP), a leader in formulation and capsule manufacturing for the dietary supplement industry. Founded in 1995, HWP is located in Clackamas, Oregon, USA, and is a privately-owned and long-time business partner of IFF’s Health & Biosciences probiotics business. HWP is a global leader in the consumer Health and Nutrition industries, providing the highest-quality nutritional supplement...

Read More
news image

GLOBAL CRISPR AND CRISPR-ASSOCIATED (CAS) GENES MARKET INSIGHTS 2019-2025

Galus | April 14, 2020

Manufacturing process and technology used in CRISPR And CRISPR-Associated (Cas) Genes market, key developments and trends changing in the development Complete examination, including an evaluation of the parent market...

Read More
news image

CELL AND GENE THERAPY

BIO-TECHNE SIGNS LICENSE AGREEMENT WITH LUMINARY THERAPEUTICS FOR THE USE OF TCBUSTER™ FOR THE MANUFACTURING OF GENE-MODIFIED CELL THERAPIES

Bio-Techne | February 25, 2021

Bio-Techne Corporation today declared the signing of a license agreement with Luminary Therapeutics for the utilization of TcBuster™ for the manufacturing of gene-modified cell therapies. TcBuster is Bio-Techne's proprietary non-viral transposon-based gene delivery system used to advance cell therapy manufacturing. Under the provisions of this agreement, Bio-Techne grants Luminary Therapeutics a non-exclusive license for TcBuster. Luminary Therapeutics will utilize TcBus...

Read More
news image

CAMENA BIOSCIENCE HITS DNA SYNTHESIS MILESTONE

Labiotech | February 06, 2020

Camena Bioscience has achieved a significant DNA synthesis milestone by reproducing the DNA sequence of a whole plasmid, which could be used in synthetic biology applications such as protein production and bacterial engineering. DNA synthesis is a field that, until recently, had not been a focus for companies developing innovative technologies, with greater importance being placed on DNA sequencing and manipulation tools....

Read More
news image

INDUSTRIAL IMPACT

IFF TO ACQUIRE HEALTH WRIGHT PRODUCTS

IFF | February 17, 2022

IFF announced that it has entered into an agreement to acquire Health Wright Products, LLC (HWP), a leader in formulation and capsule manufacturing for the dietary supplement industry. Founded in 1995, HWP is located in Clackamas, Oregon, USA, and is a privately-owned and long-time business partner of IFF’s Health & Biosciences probiotics business. HWP is a global leader in the consumer Health and Nutrition industries, providing the highest-quality nutritional supplement...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us